Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies

Drug Profile

Research programme: orthopoxvirus infections therapeutics - TransTech Pharma/SIGA Technologies

Alternative Names: TTP 018

Latest Information Update: 23 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SIGA Technologies; TransTech Pharma
  • Class Small molecules; Viral vaccines
  • Mechanism of Action Peptide hydrolase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Orthopoxvirus infections

Most Recent Events

  • 21 Sep 2010 No development reported - Preclinical for Orthopoxvirus infections in USA (unspecified route)
  • 25 Jul 2007 TTP 018 is in preclinical development
  • 31 May 2004 This programme is still in active development - 17th International Conference on Antiviral Research (ICAR-2004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top